3D Signatures (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0)

By | June 6, 2017

Potential Massive Breakout for DXD!

Good Morning Everyone,

We’d like to call your attention to 3D Signatures, Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0). They are getting ready for a Potential Massive Breakout!

3D Signatures, Inc. (DXD) is a personalized medicine company which is poised to REVOLUTIONIZE THE DIAGNOSTICS AND TREATMENT FOR CANCERS AND NEUROLOGICAL DISORDERS.

 

POINTS OF INTEREST :

DXD is currently developing 5 diagnostic, prognostic and risk predictive tests that can measure disease stage and genomic stability, drug efficacy, and potential side effects for:

  • Hodgkin’s Lymphoma
  • Prostate Cancer
  • Multiple Myeloma
  • Lung Cancer
  • Alzheimers

DXD’s disruptive technology platform could represent a new class of biomarkers for these diseases, which could tell doctors how to personalize treatment and best manage the disease for each individual patient, improving their outcome.

DXD’s technology would not only predict the course of the disease, but would also enable pharmaceutical companies to identify and develop more effective drugs.

DXD’s proprietary software provides a three-dimensional analysis of a patient’s individual chromosomal arrangement- or signature – through a simple, non-invasive blood test or tissue sample.

THIS IS TRULY GAME-CHANGING!


WHY IS DXD ON OUR RADAR?:

  • DXD’s TeloviewTM software platform is attracting attention of multinational healthcare companies.
  • 3D Signature is helmed by an expert team with successful track record in biomedical market. CEO and Director, Jason Flowerday has two decades of executive life sciences management and start-up experience. Prior to joining 3D Signatures, he worked at two of the world’s largest pharmaceutical companies, Germany’s Bayer AG and U.S.-based Johnson and Johnson before expanding his successful career into leading specialty pharmaceutical, biotech and device companies in their pursuit of growth and capital. Jason is also a Director of Aequus Pharmaceuticals (TSX-V: AQS), which allows him to leverage his network and apply his specialty pharma experience.
  • Exceptional timing ahead of important catalysts. 3D Signatures is expected to announce ongoing positive news, including talent acquisition, clinical trial progress and new business developments.
  • Software as a Service (SaaS) Model. 3D Signatures is building a highly scalable SaaS based business with high margins and low overhead. Their proprietary software never leaves the Company’s server while raw digital data can be collected and analyzed from partner labs located around the world.

Good trading!
The Team


COMPANY PROFILE:

3DS (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at www.3dsignatures.com.


VIDEOS

HOW 3D SIGNATURES’ TECHNOLOGY HELPS DETECT HODGKIN’S LYMPHOMA & ALZHEIMER’S
(April 25, 2017) 3D Signatures’ CEO Jason Flowerday shares the company’s latest progress in validating the disruptive technology behind the TeloView Platform and the upcoming catalysts for 2017.

3D Telomere Technology


IN THE NEWS

3D SIGNATURES ADVANCES HODGKIN’S LYMPHOMA TEST                                                                            TORONTO, ON (June 8, 2017) − 3D Signatures Inc. (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) (the “Company” or “3DS”), is pleased to announce that the clinical trial component (the “Clinical Trial”) of its Hodgkin’s lymphoma (“HL”) test (“Telo-HL”) validation program is successfully underway. This process is referred to as Stage 3 of the validation program as set out in the Company’s news release dated February 23, 2017. Assay development and assay validation, Stage 1 and Stage 2 of the validation program, respectively, were completed on schedule. The Clinical Trial is expected to be complete by Sept 30, 2017.

3D SIGNATURES ORD (TDSGF) Stock Is Flier
(WeeklyRegister.com – June 2, 2017) – Interested investors have been looking for information on shares of 3D SIGNATURES ORD (OTCMKTS:TDSGF) after the stock moved $-0.012, hitting the $0.61 price point in a recent trade.
It’s the latest price, but let’s analyze how the stock has been doing recently. In the past year, 3D SIGNATURES ORD’s stock was big mover. According to the short interest report published recently, (TDSGF) had 35,000 shorted shares for 0.8 days to cover. The prior short interest was 35,000 for a $N/A change. The 52-Week High and Low are noted here. -27.38 % (High), 74.29 %, (Low). The stock had 43,400 average volume.

TeloView Measures Genomic Stability To Predict Disease Aggressiveness
(MedicalResearch.com – May 15, 2017) – Interview with:3D Signatures’ Jason Flowerday, CEO and Director of 3D Signatures
MedicalResearch.com: What is the background for 3D Signatures?
Response: 3D Signatures, and its clinical lab tests, which incorporate its proprietary TeloViewTM software analytics, is the culmination of over 20 years of ground-breaking research conducted by Dr. Sabine Mai and her colleagues. It is the only technology in the world that quantifies genomic instability, which is the hallmark of cancer and other proliferative diseases at the whole-cell level.

The Life Sciences Report Examines How 3D Signatures’ Platform Taps into the Power of the Genome
SAN FRANCISCO, CA–(Marketwired – May 11, 2017) – How fast is my cancer progressing? Does this treatment present my best option for a cure? These two big questions, which determine outcomes for patients with serious diseases such as Hodgkin’s lymphoma, prostate cancer and Alzheimer’s disease, are addressed by the platform technology in development by 3D Signatures Inc.. In this interview with The Life Sciences Report, 3DS’s new Chief Scientific Officer, Dr. Kevin Little, describes the TeloView platform, its utility in the marketplace and what makes it a compelling investment.

3-D imaging of telomeres inside cells aids cancer diagnosis, treatment
(Pittsburgh Post-Gazette — May 9, 2017) – Discovery, the goal of science, can frustrate medical scientists when their findings can’t be used to help people. That was the case more than a decade ago for Hans Knecht, chief hematologist at McGill University in Montreal, when he realized that telomeres were key players in Hodgkin’s lymphoma but he needed a way to advance his research. Dr. Knecht said he was stuck: “I’m a translational researcher,” he said, referring to the idea of translating discoveries into diagnostic tools and treatments. “I couldn’t go any further.”


DISCLAIMER ​
This report/release is a commercial advertisement and is for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list. The track record, gains, upside, and/or losses mentioned are all hypothetical and should not be considered as the basis for investment.
This report/release is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Reports/releases distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should read and review, if and to the extent available, any information concerning a marketed company available at the web sites of the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov ;the Financial Industry Regulatory Authority (the “FINRA”) at www.FINRA.org and your State Securities Administrator. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm , as well as related information published by the FINRA on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence.

You agree and acknowledge that any hyperlinks to the website of (1) an client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in our disseminated reports/releases is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any company mentioned here.
InvestmentQA.com is compliant with the Can Spam Act of 2003. InvestmentQA.com does not offer such advice or analysis, and InvestmentQA.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
We have not determined if the statements and opinions of the message are accurate, correct or truthful. The profiles we publish are compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because virtually all information relied upon by us in preparing an Issuer profile comes from a public source which has been made public directly from the Issuer, the information is not confirmed with a second source.
The purpose of this report/release, like any promotion, is to provide publicity for the client company, its products or services. Owners and operators of InvestmentQA.com have received monetary compensation, via bank wire, earned upon receipt, for distribution of our opinions and publicly available information for DXD from Sierro Publishing on 06/05/17. Owners and operators of InvestmentQA.com do not own any equity nor debt in DXD as of 06/06/17. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment.

You are receiving this report/release because you subscribed to receive it at our website or through a third party site.  All of our newsletters include an “unsubscribe” link, and you can remove yourself at any time from our newsletters by clicking on that “unsubscribe” link. You can also contact us at info@InvestmentQA.com to change your information at any time.  By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer which can be read at any time at www.InvestmentQA.com/Disclaimer .